Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
02:35pm, Thursday, 07'th May 2026
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
10:00am, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to con
ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors
09:16am, Thursday, 07'th May 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or the "
ADMA Biologics Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
08:20am, Thursday, 07'th May 2026
Boston, Massachusetts--(Newsfile Corp. - May 7, 2026) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in t
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
04:51am, Thursday, 07'th May 2026
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
BREAKING: ADMA Biologics Shares Fall Over 24%; Investors Encouraged to Contact Block & Leviton to Possibly Recover Losses
06:57pm, Wednesday, 06'th May 2026
Block & Leviton is investigating ADMA Biologics, Inc. (Nasdaq: ADMA) for potential securities fraud. Investors should contact the firm to recover losses.
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Wednesday, 06'th May 2026
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Y
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the fed
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
11:41am, Tuesday, 05'th May 2026
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Andrew Sather: Why Some Stock Buybacks Are Basically “Putting Money on Fire”
10:57am, Monday, 04'th May 2026
Stock buybacks have become one of the most misunderstood tools in corporate finance.
RAMSEY, N.J. and BOCA RATON, Fla.
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the fed
NEW YORK, May 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologic
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
09:30am, Sunday, 03'rd May 2026
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher.
